SCHEMBL189149

SCHEMBL189149

CC(N)COC(N)=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16103647 1.00
Hydrochloric Acid SCHEMBL29156232 0.97
Hydrochloric Acid SCHEMBL29156236 0.97
Butane SCHEMBL28176265 0.91 ALOX15 (0.46)
Butylamine SCHEMBL29114693 0.82 ALOX15 (0.39)
SCHEMBL28160740 0.81 TSHR (0.44)
SCHEMBL30357063 0.81 ALOX15 (0.50)
SCHEMBL42755 0.81
SCHEMBL28101728 0.80 ALOX15 (0.44)
SCHEMBL28101763 0.80 ALOX15 (0.44)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111295368-A Chemically activated water soluble prodrugs 大日本住友制药株式会社 2020-06-16 CN claimed
CN-119841776-A Tyrosine kinase inhibitors and uses thereof 华上生技医药股份有限公司 2025-04-18 CN disclosed
US-20240199654-A1 CTLA-4 SMALL MOLECULE DEGRADATION AGENT AND APPLICATION THEREOF SUZHOU GUOKUANG PHARMTECH. CO., LTD. (CN) 2024-06-20 US disclosed
CN-114072207-B Bicyclic compounds 维瓦斯治疗公司 2024-03-29 CN disclosed
EP-4310081-A1 CTLA-4 SMALL MOLECULE DEGRADATION AGENT AND APPLICATION THEREOF Suzhou Guokuang Pharmtech. Co., Ltd. (CN) 2024-01-24 EP disclosed
CN-117222646-A KRAS G12C inhibitors and uses thereof 苏州赞荣医药科技有限公司 2023-12-12 CN disclosed
CN-117157284-A CTLA-4 small molecule degradation agent and application thereof 苏州国匡医药科技有限公司 2023-12-01 CN disclosed
WO-2023040989-A1 KRAS G12C INHIBITORS AND USES THEREOF SUZHOU ZANRONG PHARMA LIMITED (CN) 2023-03-23 WO disclosed
CN-115443276-A Pyridopyrimidinone derivatives and their use as modulators of aromatic hydrocarbon receptors 东亚ST株式会社 2022-12-06 CN disclosed
CN-108351169-B Proteasome inhibitors and uses thereof 康奈尔大学 2022-01-28 CN disclosed
CN-103282352-B Benzamides and nicotinamide as SYK regulator 波托拉医药品公司 2016-08-10 CN disclosed
EP-2401263-B1 SUBSTITUTED AZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVES, AND METHOD FOR TREATING PARKINSON'S DISEASE USING THE SAME SK BIOPHARMACEUTICALS CO LTD (KR) 2016-02-17 EP disclosed
US-8841257-B2 Inhibitors of STAT3 and uses thereof BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2014-09-23 US disclosed
US-8828992-B2 Substituted azole derivatives, pharmaceutical composition containing the derivatives, and method for treating Parkinson's disease using the same SK BIOPHARMACEUTICALS CO., LTD. (KR) 2014-09-09 US disclosed
CN-103282352-A Benzamides and nicotinamides as syk modulators PORTOLA PHARM INC 2013-09-04 CN disclosed
US-20120035114-A1 INHIBITORS OF STAT3 AND USES THEREOF BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2012-02-09 US disclosed
EP-2401263-A2 SUBSTITUTED AZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVES, AND METHOD FOR TREATING PARKINSON'S DISEASE USING THE SAME SK Biopharmaceuticals Co., Ltd. (KR) 2012-01-04 EP disclosed
US-20110301150-A1 SUBSTITUTED AZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVES, AND METHOD FOR TREATING PARKINSON'S DISEASE USING THE SAME SK BIOPHARMACEUTICALS CO., LTD. 2011-12-08 US disclosed
WO-2010118309-A2 INHIBITORS OF STAT3 AND USES THEREOF BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2010-10-14 WO disclosed
WO-2010098600-A2 SUBSTITUTED AZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVES, AND METHOD FOR TREATING PARKINSON'S DISEASE USING THE SAME SK HOLDINGS CO., LTD. (KR) 2010-09-02 WO disclosed